Trial intelligence / Profile preview

ANT-1207 in Subjects With Lateral Canthal Lines

NCT01358695Phase 2

Key facts

Status: Completed
Start: May 2011
Primary completion: Feb 2012
Countries: 1
Sponsor: Anterios, Inc.
Modality: Recombinant Proteins and Enzymes

Drugs: botulinum toxin type A
Conditions: lateral canthal rhytides

Overview

Phase 2, randomised, double-blind trial of botulinum toxin type A in lateral canthal rhytides (6 arms), sponsored by Anterios, Inc. Primary endpoint: Investigator's Global Assessment at 2 weeks. Started May 2011; status: completed.

Design

6 arms

Study design: RandomizedDouble-blind

Placebo Comparator
Placebo
Dose 1
ANT-1207 Dose 1
Dose 2
ANT-1207 Dose 2
Dose 3
ANT-1207 Dose 3
Dose 4
Botulinum Toxin Type A Dose 4
Dose 5
Botulinum Toxin Type A Dose 5

Who it enrols

Adult subjects with mild to moderate Crow's Feet wrinkles (IGA 2-3) at rest and moderate to severe Crow's Feet (IGA 3-4) on contraction. Excludes subjects with history of peri-ocular surgery or recent procedures in the lateral canthal region.

Endpoints

Primary

Investigator's Global Assessment2 weeks

Secondary

Subject Self Assessment2 weeks
Investigator's Global Assessment12 weeks

Beyond the preview

Go deeper on NCT01358695.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01358695.